Immunomodulation Therapy to Treat Severe Malaria With Multiple Organ Failure.
This report describes adjunctive selective cytopheretic device therapy during continuous renal replacement therapy in a 5-year-old girl with severe falciparum malaria, AKI, shock, and multiple organ dysfunction, followed by improvement in inflammatory markers, vasopressor needs, acidosis, and organ function.
Open original publication →What the AI sees
This report describes adjunctive selective cytopheretic device therapy during continuous renal replacement therapy in a 5-year-old girl with severe falciparum malaria, AKI, shock, and multiple organ dysfunction, followed by improvement in inflammatory markers, vasopressor needs, acidosis, and organ function.
Research significance
The reported temporal improvement after SCD initiation provides an early clinical signal; it can be hypothesized—but not concluded from this single uncontrolled case—that extracorporeal leukocyte immunomodulation may reduce maladaptive inflammation and support organ recovery in severe malaria.
Source abstract
BACKGROUND: Malaria causes more than 600,000 deaths annually. Severe malaria is frequently complicated by acute kidney injury (AKI) and multiple organ failure driven by dysregulated host hyperinflammation. Elevated cytokines, including interleukin-6 and tumor necrosis factor alpha, are associated with disease severity and mortality, yet effective adjunctive immunomodulatory therapies are lacking. We report the first clinical use of the selective cytopheretic device (SCD), an extracorporeal immunomodulatory therapy, in severe malaria. CASE SUMMARY: A 5-year-old girl returning from the Democratic Republic of the Congo presented with fever, shock, 10.9% parasitemia, AKI, and evolving multiple organ dysfunction. Despite IV artesunate and RBC exchange, she developed refractory shock and severe lactic acidosis. Continuous renal replacement therapy with adjunctive SCD therapy was initiated, after which inflammatory markers, vasopressor requirements, and metabolic acidosis improved with progressive organ recovery. CONCLUSIONS: Targeted extracorporeal immunomodulation may represent a promising adjunctive strategy for severe malaria.